Welcome to our dedicated page for PRESSURE BIOSCIENCES news (Ticker: PBIO), a resource for investors and traders seeking the latest updates and insights on PRESSURE BIOSCIENCES stock.
Pressure BioSciences, Inc. (PBIO) is a forefront life sciences company that focuses on the development and commercialization of an innovative platform technology known as Pressure Cycling Technology (PCT). This technology employs cycles of hydrostatic pressure, ranging from ambient to ultra-high levels (up to 35,000 psi and beyond), to precisely control biomolecular interactions, offering significant advancements in various scientific fields.
The company's core business revolves around leveraging PCT to enhance the analysis, study, and manipulation of biological samples. This technology has broad applications in areas such as protein characterization, pathogen inactivation, and the preparation of samples for genomic and proteomic studies. By utilizing PCT, researchers and scientists can achieve higher yields, improved quality, and better consistency in their biological analyses.
Recently, PBIO has made notable strides with the introduction of its new consumer products business unit, Uncle Bud’s. In January 2024, the company kicked off with a substantial $252,000 shipment of its Sunburn Soother to one of the world’s largest retailers, showcasing strong market demand and consumer interest. Additionally, VICAR Holdings LLC has committed to purchasing over 10,000 bottles of PBIO's best-in-class Nano-CBD topical spray in 2024, indicating a promising trajectory for their consumer products segment.
PBIO's relocation to a new facility has significantly increased their manufacturing space, enhanced operating efficiencies, and achieved measurable cost savings, setting the stage for unencumbered growth through multi-year expansion plans. The new facility is expected to support the company's long-term strategy and scale operations to meet growing demand.
Uncle Bud's acquisition has already yielded early synergies and measurable performance metrics within the first month, boosting PBIO's market presence and consumer engagement. This positive momentum highlights PBIO's capability to integrate and scale operations effectively.
Furthermore, Pressure BioSciences’ UltraShear platform continues to showcase its potential by enabling the development and launch of health and wellness products with groundbreaking bioavailability, fast onset, and effectiveness. This platform technology is a testament to PBIO's commitment to innovation and enhancing the quality and effectiveness of bio-molecular research and consumer applications.
Pressure BioSciences (OTCQB:PBIO) will present at the Sequire Cannabis & Psychedelics Investor Conference on April 20, 2022, at 10:30 am EDT. CEO Richard T. Schumacher will discuss the company's recent advancements in nanoemulsification of CBD and other cannabinoids, along with the planned commercialization of their Ultra Shear Technology™ platform in Fall 2022. This event will feature over 30 public companies in the cannabis and psychedelics space, showcasing innovations in the biopharmaceutical and related industries.
Pressure BioSciences, Inc. (OTCQB:PBIO) reported a 91% revenue increase for Q4 2021 and a 64% increase for FY2021 compared to 2020. Key product lines, including instruments and consumables, showed significant growth, with instrument sales rising to $1,105,268. Despite this revenue growth, the operating loss for FY2021 was $4,185,147, slightly improved from $4,585,787 in FY2020. The company plans to focus on the commercialization of its Ultra Shear Technology (UST) platform, which holds transformative potential across various markets. An investor call is scheduled for April 5, 2022.
Pressure BioSciences, Inc. (OTCQB:PBIO) will host a teleconference on April 5, 2022, at 4:30 PM ET to discuss its Fourth Quarter and Fiscal Year 2021 financial results and provide a business update. The call will be available live and through replay for 30 days afterward. PBI's innovative pressure-based solutions, including its patented Pressure Cycling Technology (PCT) and the new Ultra Shear Technology (UST), are aimed at various sectors, enhancing capabilities in biomarker discovery, drug development, and food preservation.
Pressure BioSciences (OTCQB:PBIO) reported record instrument orders in March 2022, exceeding previous monthly totals. The company is expanding its BaroFold platform services and preparing for commercialization of its Ultra Shear Technology (UST) platform. With plans to uplist to a national exchange, PBIO aims for significant revenue growth, driven by anticipated pharma contracts and new agrochemical sales. The company has improved its financial position, converting 80% of its loan debt to equity, and is on track for profitability by 2023.
Pressure BioSciences (PBIO) announced an expanding partnership with The Ohio State University and the Food Industry Consortium, focusing on the commercial release of Ultra Shear Technology (UST). The patented BaroShear UST MAX has been installed at Ohio State's Advanced Food Processing Technology Pilot Plant. This technology aims to enhance the quality and safety of liquid foods while potentially reducing chemical additives. An outreach program will launch in Spring 2022, inviting global food companies to join the Consortium, emphasizing innovations in microbiology and nutrition.
Pressure BioSciences (OTCQB: PBIO) collaborates with The Ohio State University to develop innovative ultra shear technology (UST) for liquid food preservation. This technology aims to create healthier beverages and food products without artificial preservatives, utilizing high pressure and shear forces. UST not only reduces thermal exposure but also enhances food safety by eliminating harmful pathogens. A consortium of food processors will be formed to facilitate the adoption of UST, backed by a $891,000 USDA grant. This initiative seeks to meet the growing consumer demand for clean-label products.
Pressure BioSciences (PBIO) has commissioned its BaroShear MAX UST system at The Ohio State University's Food Pilot Plant, marking a significant milestone for the company. This initiative is part of the Food Industry Consortium, which aims to enhance the quality and safety of liquid foods by utilizing Ultra Shear Technology (UST). UST promises to produce healthier products with longer shelf lives, reducing the need for chemical additives. The UST platform is poised to extend into various consumer products, including nutraceuticals, with plans to commercialize processing units in late 2022.
Pressure BioSciences, Inc. (OTCQB: PBIO) will participate in a real-time, interactive fireside chat on January 20, 2022, at noon ET, during the Innovations and Advancements in the CBD Market webinar, sponsored by FORCE Family Office. CEO Richard T. Schumacher will represent PBIO, which aims to release its Ultra Shear Technology™ platform for creating long-term stable nanoemulsions. Other panelists include ProVerde Laboratories and The Alkaline Water Company. Recent announcements from PBIO highlight advancements in CBD oil nanoemulsions and patent awards for its UST platform.
Pressure BioSciences (OTCQB:PBIO) announced a breakthrough in CBD oil processing using its patented Ultra Shear Technology (UST) platform. The technology produces water-soluble nanoemulsions of CBD that have demonstrated stability for over 18 months. This innovation addresses the low absorption rates of traditional CBD products, which the WHO estimates at only 6%. The stability and clarity of the CBD nanoemulsions could revolutionize applications in food and therapeutic markets. The global CBD market is projected to grow significantly, providing potential for rapid adoption of UST systems by customers in 2022.
Pressure BioSciences (PBIO) reported Q3 2021 financial results, showing total revenue of $518,000, a 3% decline year-over-year. Instrument sales fell by 12%, while consumables also decreased by 7%. However, BaroFold/UST services rose by 18%. Year-to-date, total revenue was $1,687,000, up 60%. The operating loss for Q3 2021 increased by 51% to $1,243,000. Despite challenges, the company anticipates strong growth in 2022, including significant agrochem revenue increases and the launch of the UST platform.
FAQ
What is the current stock price of PRESSURE BIOSCIENCES (PBIO)?
What is the market cap of PRESSURE BIOSCIENCES (PBIO)?
What is Pressure BioSciences, Inc. (PBIO)?
What is Pressure Cycling Technology (PCT)?
In which areas is PCT technology applied?
What recent achievements has PBIO made?
What is Uncle Bud’s?
How has PBIO's new facility impacted the company?
What is the UltraShear platform?
How has Uncle Bud’s performed since its acquisition?
What are some applications of PBIO’s products?
What is the significance of PBIO’s consumer products?
